We are aiming to create the world's most productive drug discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients.
We have state-of-the-art suite of proprietary technologies across the drug discovery process and accesses further innovative capabilities and expertise through our growing network of partners.
Our advancing pre-clinical discovery portfolio is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division.
Our business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, we successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m.
The Company, founded as a spin-out from the University of Manchester, is led by a highly experienced management team and Board who have historically delivered significant value creation within the healthcare sector.